Related references
Note: Only part of the references are listed.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
Ning Tang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
On the use of corticosteroids for 2019-nCoV pneumonia
Lianhan Shang et al.
LANCET (2020)
Convalescent plasma as a potential therapy for COVID-19
Long Chen et al.
LANCET INFECTIOUS DISEASES (2020)
First Case of 2019 Novel Coronavirus in the United States
Michelle L. Holshue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Ahmet Kursat Azkur et al.
ALLERGY (2020)
More on COVID-19 coagulopathy in Caucasian patients
Helen Fogarty et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Bin Zhang et al.
CHEST (2020)
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
Wen Zhang et al.
CLINICAL IMMUNOLOGY (2020)
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
N. Lian et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19
Bharat Damle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Zhe Xu et al.
LANCET RESPIRATORY MEDICINE (2020)
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Christian A. Devaux et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Emanuele Pontali et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal
Hasan K. Siddiqi et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Dandan Wu et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
TMPRSS2 and COVID-19: serendipity or Opportunity for Intervention?
Konrad H. Stopsack et al.
CANCER DISCOVERY (2020)
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Matthieu Million et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Philippe Gautret et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
ISTH interim guidance on recognition and management of coagulopathy in COVID-19
Jecko Thachil et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome
Marco Ranucci et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Rami Sommerstein et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Mandeep R Mehra et al.
LANCET (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Interferon-α2b Treatment for COVID-19
Qiong Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
Wei Cao et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Joshua Geleris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
Marta Colaneri et al.
MICROORGANISMS (2020)
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
Fang Liu et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial
Ling Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial
Mayla Gabriela Silva Borba et al.
JAMA NETWORK OPEN (2020)
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial
Spyridon G. Deftereos et al.
JAMA NETWORK OPEN (2020)
撤稿声明: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis (Retraction of 10.1016/S0140-6736(20)31180-6, 2020)
Mandeep R. Mehra et al.
LANCET (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
Sara De Biasi et al.
NATURE COMMUNICATIONS (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Juan Meng et al.
EMERGING MICROBES & INFECTIONS (2020)
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia
Ling Lin et al.
EMERGING MICROBES & INFECTIONS (2020)
Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine
Nihong Lu et al.
3 BIOTECH (2019)
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini et al.
MBIO (2018)
IVIG-mediated effector functions in autoimmune and inflammatory diseases
Caroline Galeotti et al.
INTERNATIONAL IMMUNOLOGY (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Arbidol as a broad-spectrum antiviral: An update
Julie Blaising et al.
ANTIVIRAL RESEARCH (2014)
Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation
Thomas Kuri et al.
JOURNAL OF GENERAL VIROLOGY (2009)
Chemically modified tetracyclines induce apoptosis in cultured mast cells
C Sandler et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Role of interferons in the treatment of severe acute respiratory syndrome
J Cinatl et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome - A preliminary study
MR Loutfy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
